News | November 28, 2024
Granules' net zero commitment approved by SBTi
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
The product will be marketed by Dr. Reddy's
Emcure has launched an awareness campaign to help spread the word about male anemia
Modernization and supply chain diversity drive new growth
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
Stable profits, low leverage to keep credit profiles comfortable
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
